- Trials with a EudraCT protocol (103)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
103 result(s) found for: Cross Infection.
Displaying page 1 of 6.
EudraCT Number: 2014-004522-17 | Sponsor Protocol Number: NACAHvs.1.1 | Start Date*: 2015-03-06 |
Sponsor Name:Imperial College London & Imperial College Healthcare NHS Trust | ||
Full Title: The mechanism of action of N-ACetylcysteine for reducing the risk of Infection in Alcoholic Hepatitis | ||
Medical condition: Alcoholic hepatitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005576-35 | Sponsor Protocol Number: CP-PRO-CoVLP-021 | Start Date*: 2021-05-06 | |||||||||||
Sponsor Name:Medicago R&D Inc. | |||||||||||||
Full Title: A Randomized, Observer-Blind, Placebo-Controlled, Phase 2/3 Study to Assess the Safety, Efficacy, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18 Years o... | |||||||||||||
Medical condition: Covid-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-004166-37 | Sponsor Protocol Number: 100424 | Start Date*: 2023-05-02 |
Sponsor Name:Division of Thoracic and Hyperbaric Surgery, Medical University Graz | ||
Full Title: Hyperbaric oxygenation for patients with orthostatic dysregulation (postural orthostatic tachycardia) in Long- COVID. Prospectively randomized cross- over study. | ||
Medical condition: Multiorgan symptoms after COVID-19 infection (Long COVID) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-002287-31 | Sponsor Protocol Number: PREVICHARM | Start Date*: 2020-05-22 | |||||||||||
Sponsor Name:FIMABIS | |||||||||||||
Full Title: Prevention of COVID19 infection with hydroxychloroquine in institutionalized older people and nursing home staff. An open, randomized controlled stepped-wedge clinical trial by clusters. PREVICHARM... | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002636-31 | Sponsor Protocol Number: APHP211034 | Start Date*: 2022-09-15 |
Sponsor Name:Assistance Publique Hôpitaux de Paris/DRCI | ||
Full Title: Piperacillin-tazobactam and temocillin as carbapenem-alternatives for the treatment of severe infections due to extended-spectrum beta-lactamase–producing Gram-negative Enterobacteriaceae in the in... | ||
Medical condition: severe infections due to extended-spectrum beta-lactamase–producing Gram-negative Enterobacteriaceae | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2011-001871-37 | Sponsor Protocol Number: LTN0001 | Start Date*: 2011-06-06 | |||||||||||||||||||||
Sponsor Name:Department of Infectious Diseases - Aarhus University Hospital | |||||||||||||||||||||||
Full Title: Immune Response to Bivalent or Tetravalent Human Papillomavirus Vaccine in HIV infected Adults | |||||||||||||||||||||||
Medical condition: HIV Human Papilloma Virus | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-002076-16 | Sponsor Protocol Number: 109563 | Start Date*: 2012-04-12 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||
Full Title: Clinical Otitis Media and Pneumonia Study (COMPAS): a phase III , double-blind, randomized, controlled, multicentre study to demonstrate the efficacy of GlaxoSmithKline (GSK) Biologicals’ 10-valent... | ||||||||||||||||||
Medical condition: Three dose primary vaccination of healthy infants between 6-16 weeks of age at the time of the first vaccination, followed by a booster dose at 15-18 months. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-002880-26 | Sponsor Protocol Number: AI424-128 | Start Date*: 2005-04-06 |
Sponsor Name:Bristol-Myers Squibb International Corporation | ||
Full Title: A Phase IV, Multi-center, Cross-sectional study to evaluate the I50L substitution among subjects experiencing virologic failure on a HAART regimen containing atazanavir (ATV) Protocol: version 2.0... | ||
Medical condition: Subjects experiencing virologic failure after a HAART regimen containing ATV | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) DE (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2015-001023-23 | Sponsor Protocol Number: CUTHIVAC002 | Start Date*: 2015-08-24 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: A Phase I clinical trial to assess the safety and immunogenicity of HIV DNA-C CN54ENV immunisations administered via the Intramuscular and Intradermal methods with and without electroporation follo... | |||||||||||||
Medical condition: HIV prophylaxis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003450-22 | Sponsor Protocol Number: P-105-303 | Start Date*: 2022-03-08 | |||||||||||
Sponsor Name:AlloVir, Inc. | |||||||||||||
Full Title: Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, with Cross-Over, of Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standar... | |||||||||||||
Medical condition: AdV infection in pediatric and adult allo HCT recipients receiving standard of care | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) IT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000959-33 | Sponsor Protocol Number: CTP G007.04 | Start Date*: 2007-08-16 |
Sponsor Name:PARI GmbH | ||
Full Title: Randomized, open labelled, cross over deposition study of Tobramycin 100 PARI nebulized with eFlow® versus TOBI® nebulized with PARI LC PLUS® in subjects with CF | ||
Medical condition: Cystic Fibrosis with Pseudomonas aeruginosa infection | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-005492-13 | Sponsor Protocol Number: TMC207TBC1002 | Start Date*: 2013-03-26 | |||||||||||
Sponsor Name:Janssen infectious diseases BVBA | |||||||||||||
Full Title: A Phase I, open-label, randomized, 3-way crossover study in 3 Panels of healthy, adult subjects to assess the relative bioavailability of TMC207 following single-dose administration of two pediatri... | |||||||||||||
Medical condition: Multi-drug resistant tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001325-14 | Sponsor Protocol Number: 580299/008 | Start Date*: 2004-08-12 |
Sponsor Name:GlaxoSmithKline SA | ||
Full Title: Estudio en fase III, doble ciego, aleatorizado, controlado, multicéntrico para evaluar la eficacia de la vacuna HPV-16/18 VLP/AS04 de GlaxoSmithKline Biologicals comparada con la vacuna antihepatit... | ||
Medical condition: cervical cancer => study is conducted in healthy female | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-006773-32 | Sponsor Protocol Number: HPV_CSP01 | Start Date*: 2009-05-20 | |||||||||||
Sponsor Name:Health Protection Agency | |||||||||||||
Full Title: A Phase IV, randomised study to evaluate the immune responses of UK adolescent girls receiving Cervarix(TM) or Gardasil(TM) Human Papillomavirus vaccines | |||||||||||||
Medical condition: This study will investigate vaccines that prevent premalignant cervical lesions and cervical cancer causally related to Human Papillomavirus (HPV) types 16 and 18. This study will investigate wheth... | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001781-35 | Sponsor Protocol Number: UKER-BC007-01 | Start Date*: 2023-05-16 | |||||||||||
Sponsor Name:Universitätsklinikum Erlangen | |||||||||||||
Full Title: Prospective, explorative, randomized, controlled, double-blind, cross-over phase IIa clinical trial to investigate safety and tolerability as well as potential clinical effects of BC007 in patients... | |||||||||||||
Medical condition: Post-COVID syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004380-58 | Sponsor Protocol Number: A3711045 | Start Date*: 2007-03-15 | |||||||||||
Sponsor Name:Pfizer Limited | |||||||||||||
Full Title: A MULTI-CENTER, RANDOMIZED, CROSS-OVER, DOUBLE-BLIND, THIRD PARTY OPEN, PLACEBO CONTROLLED, PILOT STUDY TO ASSESS THE URODYNAMIC EFFECTS OF MODIFIED RELEASE UK-369,003 IN MEN WITH LOWER URINARY TRA... | |||||||||||||
Medical condition: Lower Urinary Tract Symptoms | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: NL (Completed) CZ (Completed) LV (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004657-24 | Sponsor Protocol Number: 7985 | Start Date*: 2014-10-24 | |||||||||||
Sponsor Name:Southampton University | |||||||||||||
Full Title: A randomised, double-blind, placebo controlled, feasibility study exploring the role of Chinese herbal medicine in the treatment of women with recurrent urinary tract infections. | |||||||||||||
Medical condition: Recurrent urinary tract infections | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001755-12 | Sponsor Protocol Number: 18SM4819 | Start Date*: 2019-11-12 | |||||||||||
Sponsor Name:Imperial College | |||||||||||||
Full Title: A pilot double-blind, randomised, placebo-controlled, cross-over study of metformin to reduce airway glucose in stable COPD | |||||||||||||
Medical condition: Chronic obstructive pulmonary disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-014770-17 | Sponsor Protocol Number: NVI-255 | Start Date*: 2009-10-09 |
Sponsor Name:Netherlands Vaccine Institute | ||
Full Title: New influenza A (H1N1) disease incidence and immunogenicity of the pandemic influenza A (H1N1) vaccine in healthy adults | ||
Medical condition: influenza A (H1N1) virus infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-000265-41 | Sponsor Protocol Number: V116-04 | Start Date*: 2022-08-29 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
Full Title: A Phase 3 Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults 18 to 49 Years of Age | |||||||||||||
Medical condition: Pneumococcal disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) ES (Completed) AT (Completed) DK (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
